We have located links that may give you full text access.
Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Cancer Investigation 2009 May
BACKGROUND: As one of the bacterial superantigens, Staphylococcal enterotoxins (SEs) are potent activators of T cells, especially for those expressing T cell receptor V(beta) chains, and can induce the production of cytokines such as IFN-gamma, TNF-alpha, IL-1, IL-2, IL-6, IL-12, etc. Thus, SEs could be used in tumor-targeting therapy when cooperated with the vectors that can specifically recognize the tumor cells.
MATERIALS AND METHODS: The coding sequences of Staphylococcal enterotxin B (SEB) was amplified and fused with human basic fibroblast growth factor (bFGF). Recombinant protein SEB and fusion protein bFGF/SEB were expressed and purified. The biological activity was detected, including splenocytes proliferation, cytokine production, and cytotoxicity in tumor cells in vitro. In addition, the binding of bFGF/SEB with tumor cells and the tumor cell apoptosis were also tested by immunofluorescent technique.
RESULTS: The fusion protein bFGF/SEB had similar biological activities compared with natural SEA and recombinant SEB, including tumor-inhibition ratio.
CONCLUSION: The recombinant bFGF/SEB-fusion protein was shown to retain the superantigenic activity of SEB, and might be a novel promising immunotherapeutic agent for the treatment of some carcinomas.
MATERIALS AND METHODS: The coding sequences of Staphylococcal enterotxin B (SEB) was amplified and fused with human basic fibroblast growth factor (bFGF). Recombinant protein SEB and fusion protein bFGF/SEB were expressed and purified. The biological activity was detected, including splenocytes proliferation, cytokine production, and cytotoxicity in tumor cells in vitro. In addition, the binding of bFGF/SEB with tumor cells and the tumor cell apoptosis were also tested by immunofluorescent technique.
RESULTS: The fusion protein bFGF/SEB had similar biological activities compared with natural SEA and recombinant SEB, including tumor-inhibition ratio.
CONCLUSION: The recombinant bFGF/SEB-fusion protein was shown to retain the superantigenic activity of SEB, and might be a novel promising immunotherapeutic agent for the treatment of some carcinomas.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app